## **HHS Public Access**

Author manuscript

Lung Cancer. Author manuscript; available in PMC 2021 April 08.

Published in final edited form as:

Lung Cancer. 2021 April; 154: 228. doi:10.1016/j.lungcan.2021.02.013.

## Corrigendum to "Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression" [Lung Cancer 88/2 (2015) 131–138]

Kaisheng Mao<sup>a,b,c</sup>, Fakeng Liu<sup>a,d</sup>, Xiuju Liu<sup>a</sup>, Fadlo R. Khuri<sup>a</sup>, Adam I. Marcus<sup>a</sup>, Mingsong Li<sup>c,\*\*</sup>. Wei Zhou<sup>a,\*</sup>

<sup>a</sup>The Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 32322, United States

<sup>b</sup>Department of Hepatobiliary Surgery, NanFang Hospital, Guangzhou, People's Republic of China

Department of Gastroenterology, NanFang Hospital, Guangzhou, People's Republic of China

dDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China

The authors regret that there was an error in the labelling of plasmid K78I. All the cell lines containing mutant LKB1 should be labelled K78I, not K78M, throughout this article.

The authors would like to apologise for any inconvenience caused.

<sup>\*</sup>Corresponding author at: Department of Hematology and Medical Oncology, Emory University School of Medicine, Building C, Room 4084, 1365 Clifton Rd, NE, Atlanta, GA, 30307, United States. wzhou2@emory.edu (W. Zhou). \*\*Corresponding author at: Department of Gastroenterology, NanFang Hospital, Southern Medical University, No. 1838, Northern Guangzhou Avenue, Guangzhou, Guangdong, 510515, People's Republic of China. lims@smu.edu.cn (M. Li).